UPDATE: Raymond James Upgrades ProQR Therapeutics N.V. (PRQR) to Outperform

August 11, 2022 4:05 PM EDT
Get Alerts PRQR Hot Sheet
Price: $0.81 -2.41%

Rating Summary:
    6 Buy, 6 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 4 | Down: 17 | New: 8
Join SI Premium – FREE
(Updated - August 11, 2022 4:22 PM EDT)

Raymond James analyst Steven Seedhouse upgraded ProQR Therapeutics N.V. (NASDAQ: PRQR) from Market Perform to Outperform with a price target of $2.00.

The analyst comments "Upgrade to Outperform based on high conviction “RNA editing” emerges as an impactful field of therapeutics in coming years. RNA editing (PRQR’s therapeutics are named axiomers) is tantamount to oligonucleotide therapeutics. There is no exogenous enzyme, no complex delivery (i.e., standard delivery technologies for oligos can be leveraged), and no permanent DNA damage like with CRISPR. Instead of knocking down a gene by recruiting RISC (e.g., Onpattro vs. TTR; $153M sales in 2Q22) or modulating splicing by recruiting spliceosome (e.g., Spinraza vs. SMA2; $431M sales in 2Q22), axiomers or other RNA editing guides simply recruit endogenous ADAR enzymes to modify sequence of target RNAs."

For an analyst ratings summary and ratings history on ProQR Therapeutics N.V. click here. For more ratings news on ProQR Therapeutics N.V. click here.

Shares of ProQR Therapeutics N.V. closed at $0.84 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot Upgrades, Upgrades

Related Entities

Raymond James